{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:18:09Z","timestamp":1791271089062,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,4,16]],"date-time":"2014-04-16T00:00:00Z","timestamp":1397606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To identify and characterise urinary cationic metabolites, defined as toxic factors, in patients with interstitial cystitis (\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      ) and in control subjects. To evaluate the cytotoxicity of the urinary cationic metabolite fraction of patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      vs control subjects and of individual metabolites in cultured urothelial cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods<\/jats:title>\n                    <jats:p>\n                      Cationic fractions (\n                      <jats:styled-content style=\"fixed-case\">CFs<\/jats:styled-content>\n                      ) were isolated from the urine specimens of 62 patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      and 33 control subjects by solid\u2010phase extraction.\n                      <jats:styled-content style=\"fixed-case\">CF<\/jats:styled-content>\n                      metabolites were profiled using\n                      <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\n                      <jats:sub>18<\/jats:sub>\n                      reverse\u2010phase high performance liquid chromatography (\n                      <jats:styled-content style=\"fixed-case\">RP\u2010HPLC<\/jats:styled-content>\n                      ) with\n                      <jats:styled-content style=\"fixed-case\">UV<\/jats:styled-content>\n                      detection, quantified by area\u2010under\u2010the\u2010peaks using known standards, and normalized to creatinine.\n                      <jats:styled-content style=\"fixed-case\">RP\u2010HPLC<\/jats:styled-content>\n                      and liquid chromatography (\n                      <jats:styled-content style=\"fixed-case\">LC<\/jats:styled-content>\n                      )\u2010mass spectrometry (\n                      <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>\n                      )\/tandem\n                      <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>\n                      (\n                      <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>\n                      \/\n                      <jats:styled-content style=\"fixed-case\">MS<\/jats:styled-content>\n                      ) were used to identify major\n                      <jats:styled-content style=\"fixed-case\">CF<\/jats:styled-content>\n                      peaks.\n                      <jats:styled-content style=\"fixed-case\">HTB<\/jats:styled-content>\n                      \u20104 urothelial cells were used to determine the cytotoxicity of\n                      <jats:styled-content style=\"fixed-case\">CFs<\/jats:styled-content>\n                      and of individual metabolites with and without\n                      <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\n                      amm\u2013\n                      <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>\n                      orsfall protein (\n                      <jats:styled-content style=\"fixed-case\">THP<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:styled-content style=\"fixed-case\">RP\u2010HPLC<\/jats:styled-content>\n                      analysis showed that metabolite quantity was twofold higher in patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      compared with control subjects. The mean (\n                      <jats:sc>sem<\/jats:sc>\n                      ) for control subjects vs patients was 3.1 (0.2) vs 6.3 (0.5) mAU*min\/\u03bcg creatinine (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001).\n                      <jats:styled-content style=\"fixed-case\">LC\u2010MS<\/jats:styled-content>\n                      identified 20 metabolites. Patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      had higher levels of modified nucleosides, amino acids and tryptophan derivatives compared with control subjects. The\n                      <jats:styled-content style=\"fixed-case\">CF<\/jats:styled-content>\n                      cytotoxicity was higher for patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      compared with control subjects. The mean (\n                      <jats:sc>sem<\/jats:sc>\n                      ) for control subjects vs patients was \u22122.3 (2.0)% vs 36.7 (2.7)% (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). A total of 17 individual metabolites were tested for their cytotoxicity. Cytotoxicity data for major metabolites were all significant (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001): 1\u2010methyladenosine (51%), 5\u2010methylcytidine (36%), 1\u2010methyl guanine (31%),\n                      <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                      <jats:sup>4<\/jats:sup>\n                      \u2010acetylcytidine (24%),\n                      <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>\n                      <jats:sup>7<\/jats:sup>\n                      \u2010methylguanosine (20%) and\n                      <jats:styled-content style=\"fixed-case\">L<\/jats:styled-content>\n                      \u2010\n                      <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\n                      ryptophan (16%). These metabolites were responsible for higher toxicity in patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      . The toxicity of all metabolites was significantly lower in the presence of control\n                      <jats:styled-content style=\"fixed-case\">THP<\/jats:styled-content>\n                      (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Major urinary cationic metabolites were characterised and found to be present in higher amounts in patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      compared with control subjects. The cytotoxicity of cationic metabolites in patients with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      was significantly higher than in control subjects, and control\n                      <jats:styled-content style=\"fixed-case\">THP<\/jats:styled-content>\n                      effectively lowered the cytotoxicity of these metabolites. These data provide new insights into toxic factor composition as well as a framework in which to develop new therapeutic strategies to sequester their harmful activity, which may help relieve the bladder symptoms associated with\n                      <jats:styled-content style=\"fixed-case\">IC<\/jats:styled-content>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.12603","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T08:06:40Z","timestamp":1386662800000},"page":"286-293","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Role of urinary cations in the aetiology of bladder symptoms and interstitial cystitis"],"prefix":"10.1111","volume":"114","author":[{"given":"C. Lowell","family":"Parsons","sequence":"first","affiliation":[{"name":"Department of Urology University of California (UC) San Diego Health System  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Urology University of California (UC) San Diego Health System  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Berecz","sequence":"additional","affiliation":[{"name":"Department of Urology University of California (UC) San Diego Health System  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxuan","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Biochemistry UC San Diego  La Jolla CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zupkas","sequence":"additional","affiliation":[{"name":"Department of Urology University of California (UC) San Diego Health System  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulabha","family":"Argade","sequence":"additional","affiliation":[{"name":"Department of Urology University of California (UC) San Diego Health System  San Diego USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10860.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01128-1"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.01.047"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)01100-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-007-0205-4"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65438-7"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67203-5"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.12.026"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.05.021"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01301.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-2042.2000.00165.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09843.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39897-X"},{"key":"e_1_2_6_15_1","first-page":"493","article-title":"Bladder surface glycosaminoglycans is a human epithelial permeability barrier","volume":"171","author":"Lilly JD","year":"1990","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38437-9"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63178-1"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930130503"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11691.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01829-0"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41529-1"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3430011"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.02.2699"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.07.125"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-005-3232-2"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1993.tb00720.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(87)90248-2"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12603","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12603","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:13:06Z","timestamp":1761750786000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,16]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/bju.12603"],"URL":"https:\/\/doi.org\/10.1111\/bju.12603","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,16]]},"assertion":[{"value":"2014-04-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}